An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. In order to obtain further insight as to how NVP affects HDL metabolism, the in vivo kinetics of the HDL apolipoprotein, Apo A-1, before and 6 weeks after initiation of NVP containing treatment were evaluated. In addition, the activity of the key enzymes related to HDL metabolism were assessed.

\[ Designated as safety issue: No \]
2. In order to determine the relevance of the HDL increase in decreasing cardiovascular risk in HIV-positive subjects we evaluated endothelial function (FMD) as a surrogate marker for cardiovascular disease in patients.

\[ Designated as safety issue: No \]

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

NCT01426438

HIV-1 Infection

COMPLETED PHASE2

Adherence, Efficacy and Tolerance of Once-a-day Nevirapine-based Regimen in HIV-1 Infected Patients

NCT00466180

HIV Infections

COMPLETED PHASE4

Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection

NCT00205283

HIV Infections

COMPLETED NA

Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy

NCT01976715

Acquired Immune Deficiency Syndrome Virus Acquired Immunodeficiency Syndrome Virus AIDS Virus +2 more

COMPLETED

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

NCT00021463

HIV Infections Lipodystrophy

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Metabolism, Lipids

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

PREVENTION

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nevirapine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients will be included when they meet the following criteria:

1. 18 years of age or older.
2. Ability and willingness to provide signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation.
3. Patients on stable therapy with Trizivir only (or its equivalent component drugs), for at least 6 months prior to screening.
4. Patients with plasma HIV-1-RNA \<=50 copies/mL documented on at least two occasions within 6 months prior to enrollment.
5. Documentation of plasma HIV-1 RNA of \<=50 copies/mL for \>=6 months while on Trizivir without other antiretroviral agent. Documentation will include dates and results of all viral load testing from the previous six months.
6. Ability and willingness to complete the study.

Exclusion Criteria

Patients will not be included when they meet one or more of the following criteria:

1. Previous exposure to NNRTI drugs.
2. Documented diabetes mellitus.
3. Documented hypertension (systolic \>155 mmHg and/or diastolic \>95 mmHg).
4. Fasting hypertriglyceridemia (\>5.6 mmol/L or 500 mg/dl).
5. Use of lipid-lowering medication during the 90 days prior to study enrollment.
6. Chronic active hepatitis B and/or C infection by history.
7. Anemia (Hb \<7.0 mmol/l or 11 g/dl hematocrit \<32%).
8. Active opportunistic infection or neoplasm within 3 months prior to screening visit with the exception of cutaneous Kaposi's sarcoma without evidence of progressive disease.
9. Any history of cardiovascular disease (infarction, heart failure, peripheral vascular disease, cerebrovascular disease).
10. Hepatic, renal or thyroid abnormalities, as determined significant by the Principal Investigator.
11. Pregnancy or lactation.
12. Active anticoagulation therapy (coumarin derivates, heparin).
13. History of HIV-2 infection.
14. Female patients with CD4 counts \>250 cells/mm3.
15. Male patients with CD4 counts \>400 cells/mm3. Others which can not be listed here.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No